See the DrugPatentWatch profile for stelara
The introduction of biosimilar versions of Stelara is anticipated to lead to a significant reduction in drug prices. Market analysis suggests that biosimilars could drive down the cost of Stelara therapy by as much as 50% within the first year of their availability [1]. This price decrease is a common outcome following the entry of biosimilar competitors into the market for originator biologics.
How Soon Will Stelara Biosimilars Be Available?
The timeline for Stelara biosimilar launches is influenced by patent expirations and legal challenges. In the United States, the primary patents for Stelara were set to expire in late 2023. However, these patents have faced numerous legal challenges from biosimilar manufacturers [2]. Despite these ongoing disputes, the first biosimilars for Stelara were expected to launch in the U.S. around this time, with broader market penetration anticipated in the following years [3]. In Europe, biosimilar versions of Stelara became available earlier, with launches occurring in late 2022 [4].
What is the Impact on Stelara Sales?
As biosimilars enter the market, the sales revenue for the originator drug, Stelara (ustekinumab), is projected to decline substantially. For instance, one major biosimilar manufacturer has forecasted that Stelara sales could decrease by over 40% after their biosimilar gains significant market share [5]. This erosion of sales is a direct consequence of biosimilar products offering a lower-cost alternative, leading to prescriber and payer adoption of these more affordable options.
Which Companies Are Developing Stelara Biosimilars?
Several pharmaceutical companies are actively involved in the development and potential launch of Stelara biosimilars. These include Amgen, Samsung Bioepis, Fresenius Kabi, and Teva Pharmaceuticals, among others [6]. Their efforts are focused on gaining regulatory approval for their respective biosimilar candidates, which are designed to be highly similar to Stelara in terms of safety, efficacy, and quality.
How Do Stelara Biosimilars Compare to the Original Drug?
Stelara biosimilars are highly similar to the reference product, Stelara (ustekinumab). Regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) evaluate biosimilars based on their analytical, clinical, and non-clinical data to demonstrate this similarity [7]. The goal of a biosimilar is to have no clinically meaningful differences compared to the reference biologic.
What Are the Expected Benefits of Stelara Biosimilars?
The introduction of Stelara biosimilars is expected to enhance patient access to treatment for conditions like plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. By offering a more affordable option, biosimilars can help reduce overall healthcare costs and allow more patients to benefit from these important therapies [1].
Sources:
[1] https://drugpatentwatch.com/
[2] https://drugpatentwatch.com/
[3] https://drugpatentwatch.com/
[4] https://drugpatentwatch.com/
[5] https://drugpatentwatch.com/
[6] https://drugpatentwatch.com/
[7] https://drugpatentwatch.com/